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Summary
Background: There have been no reports concerning the correlation between heart failure and
coronary artery spasm.
Methods and results: From January 2000 to December 2007, 201 patients with heart failure were
hospitalized at our institution. We could perform coronary arteriography and spasm provoca-
tion tests in 37 (22 men, 67± 11 years) out of 201 patients with heart failure before discharge.
Atrial ﬁbrillation was observed in 13 patients (35%). After controlling heart failure and 24 h ces-
sation of vasoactive drugs, pharmacological spasm provocation tests were performed. Positive
spasm was deﬁned as >90%. Coronary spasm was observed in 12 patients (32%) and multiple
spasm was recognized in 10 (83%) out of 12 patients. Though ejection fraction on admission
was not different between the two groups (42± 18% vs. 43± 11%, ns), left ventricular end-
diastolic and end-systolic dimension after medical therapy over 1 year was signiﬁcantly smaller
in patients with positive spasm than that in patients with negative spasm. There was no differ-
ence concerning medications except the administration of nitrate and nicorandil between two
groups.
Conclusions: Coronary artery spasm, especially multiple spasm, may cause transient heart
know
f Carfailure in a small part of un
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ntroduction
n Japanese patients, coronary artery spasm may involve
arious cardiac disorders, such as acute coronary syndrome,
udden cardiac death, serious arrhythmia, syncope, and
typical chest symptoms [1—4]. Severe transient ischemia
ue to coronary artery spasm may cause temporary wall
otion abnormality. If broad wall motion abnormality is
aused, coronary artery spasm may cause transient heart
ailure. In the past years, the correlation between coronary
Published by Elsevier Ireland Ltd. All rights reserved.
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artery spasm and left ventricular dysfunction was reported.
According to these reports, about one-third of patients with
dilated cardiomyopathy (DCM) had coronary spasm and mul-
tiple spasm may lead to left ventricular dysfunction [5,6].
In this article, we investigate the correlation between
provoked coronary artery spasm and heart failure. And we
also investigate the response to medical therapy in patients
with heart failure who had provoked spasm compared with
those with heart failure and negative spasm.
Methods
Study patients
From January 2000 to December 2007, 201 patients with
heart failure were hospitalized at our institution. During this
period, we performed 956 spasm provocation tests including
508 acetylcholine (ACh) tests and 448 ergonovine (ER) tests.
After controlling the state of heart failure, we could per-
form coronary arteriography and spasm provocation tests
in 37 patients before discharge. In all 37 patients, none
had signiﬁcant organic stenosis and ACh test was performed
in 26 patients and ER test was performed in 11 patients.
All 37 patients with heart failure in this study had New
York Heart Association classiﬁcation ≥grade II and necessary
medication on hospitalization. We excluded patients with
heart failure who could medicate as outpatients. As shown
in Table 1, DCM was observed in nine patients, hypertensive
cardiomyopathy (HTC) in four patients, valvular heart dis-
ease (VHD) in three patients (one aortic insufﬁciency, one
mitral valve insufﬁciency, and one mitral valve replacement
due to mitral stenosis), and other conditions were found in
the remaining 21 patients. Atrial ﬁbrillation was found in 13
patients, including 4 with atrial tachycardia induced tran-
sient heart failure. As coronary risk factors, 22 patients had
hypertension, 9 patients had dyslipidemia, 14 patients had
diabetes mellitus, and 26 patients had history of smoking.
These 37 patients were divided into two groups based on
the result of selective spasm provocation test: the spasm
Table 1 Patients’ characteristics.
Number 37
Male 28 (76%)
Age (years) 66± 11
Disease
Dilated cardiomyopathy 9 (24%)
Hypertensive cardiomyopathy 4 (11%)
Valvular heart disease 3 (8%)
Other 21 (57%)
Atrial ﬁbrillation 13 (35%)
Risk factor
Hypertension 22 (59%)
Dyslipidemia 9 (24%)
Diabetes mellitus 14 (38%)
History of smoking 26 (70%)
Acetylcholine test done 26 (70%)
Ergonovine test done 11 (30%)
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ositive group consisted of 12 patients (11 men, mean age
8± 10 years), and the spasm negative group consisted of
5 patients (17 men, mean age 65± 13 years). DCM and
TC were deﬁned according to the World Health Organiza-
ion/International Society and Federation of Cardiology Task
orce [7]. Written informed consent was obtained from all
atients before the study, and the protocol of this study was
n agreement with the guidelines of the ethical committee
t our institution.
ackground of heart failure, acute phase therapy
n hospitalization, and risk factors
efore hospitalization, rest angina was recognized in 3
atients and some chest discomfort was observed in 10
atients, and dyspnea on effort was found in 26 patients.
nly one patient had coronary spastic angina before admis-
ion. Pleural effusion was observed in 23 patients (62%) and
ulmonary edema was found in 9 patients (24%). Mechani-
al ventilation was necessary to control heart failure in two
atients (5%). Intravenous administration of diuretics was
ecessary in 21 patients (57%), human atrial natriuretic pep-
ide in 14 patients (38%), cathecholamine in 2 patients (5%),
nd all 37 patients had received oxygen inhalation.
Dyslipidemia was deﬁned as a cholesterol level
220mg/dl, a triglyceride level >150mg/dl, or a high-
ensity lipoprotein cholesterol level <40mg/dl. Diabetes
ellitus was deﬁned according to the World Health Orga-
ization criteria [8]. Systemic hypertension was deﬁned as
systolic blood pressure of >140mmHg, a diastolic blood
ressure of >90mmHg, or as patients already treated with
ntihypertensive drugs [9]. A smoking history was obtained
rom all the patients on admission. In this study, >5 years’
abitual smoking in the past was considered positive.
pasm provocation test
alcium channel blocker and nitrate/nicorandil were dis-
ontinued for >24 h before the study and nitroglycerine was
lso discontinued >4 h before the study. Cardiac catheteri-
ation was performed using the brachial artery in the fasting
tate. After control coronary arteriograms of the left coro-
ary artery (LCA) in the right anterior oblique with caudal
rojection and of the right coronary artery (RCA) in the left
nterior oblique with cranial projection were obtained by
njection of 8—10ml of contrast medium, a temporary pace-
aker was inserted into the right ventricle of each patient
nd the pacing rate was set at 45 beats/min.
ACh (Daiichi Sanky, Tokyo, Japan, 0.1 g/2ml) was
njected in incremental doses of 20, 50, and 80g in 10ml
.9% saline solution into the RCA and of 20, 50, and 100g
nto the LCA over 20 s, as previously reported [10,11].
atients were asked to report any chest pain and to grade
t from 1 to 10 points. The intensity of usual chest pain
as 10 points. A standard 12-lead electrocardiogram (ECG)
as recorded every 30 s. One minute after each intracoro-
ary injection of acetylcholine, or when usual chest pain or
igniﬁcant ischemic ST change on the ECG appeared, coro-
ary arteriograms were obtained. The time interval between
ach injection was at least 3min. ER (Fuji Seiyaku, Toyama,
apan, 0.2mg/1ml) in 0.9% saline solution was injected in
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Table 2 Comparison of background of heart failure and acute phase therapy.
Spasm positive Spasm negative
Rest angina 2 (17%) 1 (4%)
Chest discomfort 4 (33%) 6 (24%)
Dyspnea 12 (100%)** 14 (56%)
Pleural effusion 9 (75%) 14 (56%)
Pulmonary edema 3 (25%) 6 (24%)
Left ventricular ejection fraction <45% 8 (67%) 19 (76%)
B-type natriuretic peptide >100 pg/dl 11 (92%) 23 (92%)
Medical therapy in acute phase
Intravenous diuretics 9 (75%) 12 (48%)
Cathecholamine 0 2 (8%)
Human atrial natriuretic peptide 7 (58%) 7 (28%)
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Oxygen inhalation
** p < 0.05 vs. other.
otal doses of 40g/40ml into the RCA and of 64g/64ml
nto the LCA over 4min each. The time interval between
ach injection was 5min. Two minutes after completion
f each injection, or when any chest pain or ischemic ST
hanges on the ECG occurred, coronary arteriograms were
btained. Patients were asked to report any chest pain and
o grade it from 1 to 10 points. A standard 12-lead ECG was
ecorded every 30 s. After these spasm provocation tests
ere completed, an intracoronary injection of 5.0mg isosor-
ide dinitrate was administered, and coronary arteriography
as then performed in multiple projections.
During the study, arterial blood pressure and ECG lead
II) were continuously monitored on an oscilloscope with
ihon-Kohden polygraphy. In the present study, coronary
rteriograms were analyzed separately by two independent
bservers. Coronary spasm was deﬁned as transient >90%
uminal narrowing associated with and without an attack of
hest pain or ischemic ST segment changes on the ECG. Focal
pasm was deﬁned as a discrete transient vessel narrow-
ng of >90% localized in the major coronary artery, whereas
iffuse spasm was diagnosed when transient vessel narrow-
ng >90%, compared with baseline coronary angiography, was
bserved from the proximal to distal segment in the three
ajor coronary arteries.
chocardiography
chocardiography was performed on admission and after
edical therapy at least over 1 year. Left ventricular end-
iastolic and end-systolic dimension and ejection fraction
ere analyzed. After medical therapy, E/A ratio was also
xamined as a diastolic function.
tatistical analysis
ll data are presented as mean± SD. Signiﬁcant differences
ere determined with the Mann—WhitneyU-test or Wilcoxon
igned-ranks test as appropriate. Differences in frequen-
ies were analyzed with the Fisher exact probability test,
hi-squared test, or Mann—Whitney U-test. p < 0.05 was con-
idered signiﬁcant.
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(0 2 (8%)
12 (100%) 25 (100%)
esults
omparison of background of heart failure and
cute phase therapy
s shown in Table 2, before admission, no difference con-
erning the frequency of chest symptoms except dyspnea
as found between the two groups. Rest angina was rec-
gnized in one patient in the spasm negative group and
wo patients in the spasm positive group. Only one patient
ad coronary spastic angina before admission. Chest dis-
omfort was observed in six patients in the spasm negative
roup, while four patients had chest discomfort in the spasm
ositive group. Left ventricular ejection fraction <45% on
dmission was found in 67% of patients in the spasm positive
roup and 76% of those in the negative spasm group. B-type
atriuretic peptide (BNP) >100 pg/dl was also observed in
2% of both groups of patients at hospitalization. All 37
atients had either left ventricular ejection fraction <45%
r BNP >100 pg/dl. There was no difference regarding the
tate of heart failure, pleural effusion or pulmonary edema,
nd initial therapy on heart failure between the two groups.
he frequency of positive spasm in patients with
eart failure
here was no difference concerning heart disease and risk
actors between the two groups as shown in Table 3. Coro-
ary spasm was provoked in 12 (32%) out of all 37 patients
ith heart failure. Positive spasm was found in only one
CM patient (11%), one VHD patient (33%), and none in
TC patients, while positive spasm was recognized in 10
atients (48%) out of the other 21 patients. Positive spasm
as found in 5 (38%) out of 13 patients with atrial ﬁbrilla-
ion. Atrial tachycardia induced transient heart failure was
bserved in two patients in both groups. Table 4 shows that
ultiple spasm was recognized in 10 (3-vessel spasm, 5;
-vessel spasm, 5) out of 12 patients (83%). The majority
onﬁguration of provoked spasm was diffuse. During spasm
rovocation tests, ischemic ECG change was observed in 9
75%) out of 12 patients in the spasm positive group and one
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Table 3 Comparison of clinical backgrounds and risk factors between two groups.
Spasm positive Spasm negative P-value
Number 12 25
Male 11 (92%) 17 (68%) ns
Age (years) 68± 10 65± 13 ns
Acetylcholine test done 11 15 ns
Ergonovine test done 1 10 ns
Disease
Dilated cardiomyopathy 1 (8%) 8 (32%) ns
Hypertensive cardiomyopathy 0 4 (16%) ns
Valvular heart disease 1 (8%) 2 (8%) ns
Other 10 (84%) 11 (44%) ns
Atrial ﬁbrillation 5 (42%) 8 (32%) ns
Risk factor
Hypertension 5 (42%) 17 (68%) ns
Dyslipidemia 2 (17%) 7 (28%) ns
v
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tDiabetes mellitus 7 (58%)
History of smoking 11 (92%)
patient had chest pain without ischemic ECG change. Nei-
ther ischemic ECG change nor chest pain was observed in
the remaining two patients (17%).
Cardiac catheterization data before discharge
Signiﬁcant decreases concerning left ventricular end-
diastolic volume index (74± 31ml/cm2 vs. 82± 34ml/cm2,
p < 0.01), left ventricular end-systolic volume index (42± 29
vs. 46± 23, p < 0.01), left ventricular systolic volume index
(32± 12 vs. 38± 19, p < 0.01), and left ventricular end-
diastolic pressure (10± 6mmHg vs. 14± 7mmHg, p < 0.01)
before discharge were found in patients in the positive
spasm group compared to those in the negative spasm group.
However, the value of left ventricular ejection fraction was
not different between the two groups at discharge (46± 15%
t
c
b
n
g
Table 4 Coronary arteriographic ﬁndings in patients with positiv
No. Sex Age Disease Drug Spasm
RCA
1 70 M af ACh
2 73 M af ACh
3 85 M OMI ACh #4 diffu
4 71 M DCM ACh #4 diffu
5 72 M DM/HT/af ACh #4 diffu
6 52 M HT ACh #4 diffu
7 70 M Other ER
8 63 M HT/DM ACh #4 diffu
9 78 M af ACh #2 foca
10 53 M af ACh #4 diffu
11 61 M CSA ACh #2 foca
12 69 F MVR ACh #4 diffu
Ach, acetylcholine; ER, ergonovine; RCA, right coronary artery; LCX, l
left coronary artery; hypo, hypoplastic; af, atrial ﬁbrillation; HT, hyp
OMI, old myocardial infarction; MVR, mitral valve replacement; CSA, c7 (28%) ns
15 (60%) ns
s. 44± 13%, p = ns). The mean duration of coronary arteri-
graphy done after admission was 11± 9 days in patients in
he spasm negative group and 11± 8 days in patients in the
ositive spasm group.
lood data after admission
he value of serum total cholesterol (192± 42mg/dl vs.
86± 37mg/dl, p < 0.01) and triglyceride (127± 103mg/dl
s. 120± 104mg/dl, p < 0.01) was higher in patients in
he spasm negative group than those in the spasm posi-
ive group, whereas the value of low-density lipoprotein
holesterol, high-density lipoprotein cholesterol, fasting
lood sugar, glycohemoglobin, uric acid, serum creati-
ine, and hemoglobin was not different between the two
roups. Serum high sensitive C-reactive protein level was
e spasm.
provoked vessel Dose (g)
LCX LAD RCA LCA
#11 diffuse 80 100
#8 diffuse Hypo 100
se #7 focal 20 100
se #6 diffuse 80 100
se #8 focal 80 100
se #6 diffuse 80 100
#11 diffuse #7 diffuse 40 64
se #13 diffuse #8 diffuse 20 50
l #13 focal #7 focal 20 100
se #13 diffuse #8 diffuse 80 100
l #13 diffuse #7 diffuse 50 100
se #11 diffuse #6 diffuse 80 100
eft circumﬂex artery; LAD, left anterior descending artery; LCA,
ertension; DM, diabetes mellitus; DCM, dilated cardiomyopathy;
oronary spastic angina.
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Table 5 Serum B-type natriuretic peptide and echocardiographic parameters before and after therapy.
Spasm positive Spasm negative
Before After Before After
Left ventricular diastolic dimension (mm) 55 ± 8 53 ± 7b 59 ± 9 58 ± 10
Left ventricular systolic dimension (mm) 43 ± 10 39 ± 9**,b 45 ± 9 42 ± 9
Ejection fraction (%) 42 ± 18 52 ± 15** 43 ± 11 52 ± 9*
B-type natriuretic peptide (pg/dl) 427 ± 543 91 ± 78 434 ± 467 146 ± 151
n
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** p < 0.05 vs. each value of before.
b p < 0.01 vs. after (spasm negative).
ot different between two groups (0.79± 1.33mg/l vs.
.36± 0.43mg/l, p = ns).
eft ventricular function on echocardiography and
NP level after medical therapys shown in Table 5, left ventricular end-systolic dimensions
fter medical therapy were signiﬁcantly smaller in patients
n the spasm positive group, whereas no difference concern-
ng left ventricular end-diastolic and end-systolic dimension
as found before and after medical therapy in patients
p
(
i
e
p
igure 1 Chest X-ray and M-mode echocardiogram. The patient
xertional dyspnea (Table 4, case no. 8). Bilateral pleural effusion (A
as observed on admission. After the administration of human atri
ffusion disappeared (C) and, left ventricular wall motion improvedn the spasm negative group. Left ventricular end-diastolic
nd end-systolic dimension in patients in the spasm posi-
ive group was signiﬁcantly decreased after medical therapy
ompared to that in patients in the spasm negative group.
owever, left ventricular ejection fraction was signiﬁcantly
mproved after medical therapy in both groups. On follow up
chocardiography, the ratio of E/A >1.0 was observed in six
atients including four patients with pseudo-normalization
three patients in the spasm negative group and one patient
n the spasm positive group). The mean time of follow up
chocardiography after discharge was 15± 15 months in
atients in the positive spasm group and 16± 14 months
was a 63-year-old male admitted to our hospital because of
) and diffuse slightly decreased left ventricular wall motion (B)
al natriuretic peptide and oxygen inhalation, bilateral pleural
(D) at discharge (10 days after admission).
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Figure 2 Coronary arteriogram on acetylcholine test. Diffuse spasm was provoked on distal right coronary artery with 20g
ry in
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Dof acetylcholine accompanied with chest pain (A). Intracorona
circumﬂex artery and distal left anterior descending artery a
isosorbide dinitrate, no signiﬁcant stenosis was found in either
in patients in the negative spasm group. The value of BNP
was decreased in the two groups, but not signiﬁcantly. The
mean time of follow up BNP examination after discharge
was 13± 16 months in patients in the positive spasm group
and 16± 18 months in patients in the negative spasm group.
Demonstrable cases are shown in Figs. 1 and 2.
Medical therapy after discharge
As shown in Table 6, the frequency of administration
of nitrate/nicorandil in patients in the spasm positive
group was signiﬁcantly higher than in those in the
spasm negative group. No difference in the frequency
of administration of angiotensin receptor blockers (ARBs),
angiotensin-converting enzyme inhibitors (ACEIs), or statins
was observed between the two groups. Beta-blockers were
I
w
v
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Table 6 Comparisons of medication after discharge between two
Spasm positive (n = 12)
Digitalis 6 (50%)
Loop diuretics 10 (83%)
Spironolactone 6 (50%)
Beta-blocker 2 (17%)
ARB 6 (50%)
ACEI 1 (8%)
Calcium channel blocker 10 (83%)
Alpha-blocker 0
Statin 2 (17%)
Anti-coagulant 7 (58%)
Nitrate/nicorandil 7 (58%)
Beta-blocker or ARB or ACEI 8 (67%)
ARB, angiotensin receptor blocker; ACEI, angiotensin-converting enzymjection of 50g acetylcholine induced diffuse spasm on mid
panied with chest pain (B). After the administration of 5mg
ary artery (C and D).
dministered to 10 patients (40%) in the spasm negative
roup and 2 patients (17%) in the spasm positive group, but
he difference was not signiﬁcant. Calcium channel blockers
ere administered to 83% of patients in the spasm posi-
ive group and 60% of patients in the negative spasm group,
ut the difference was not signiﬁcant. Beta-blockers, ARBs,
r ACEIs were administered to 67% of patients in the posi-
ive spasm group and 76% of patients in the negative spasm
roup.
iscussionn this study, about one-third of patients with heart failure
ho had necessary medication on hospitalization had pro-
oked coronary artery spasm before discharge. Moreover,
ore than 80% of these patients with heart failure and posi-
groups.
Spasm negative (n = 25) P-value
11 (44%) ns
14 (56%) ns
8 (32%) ns
10 (40%) ns
13 (52%) ns
3 (12%) ns
15 (60%) ns
1 (4%) ns
4 (16%) ns
15 (60%) ns
6 (24%) 0.05
19 (76%) ns
e inhibitor.
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ive spasm had multiple spasms. The frequency of provoked
pasm in this study was similar to the results of Sakata et
l. [5] and Nishi et al. [6]. In Japanese patients with heart
ailure, multiple spasms may cause transient heart failure,
nd these patients with heart failure and positive spasm had
mproved left ventricular function after medical therapy,
ncluding calcium channel blockers and nitrate/nicorandil.
e ﬁrstly named this disease state vasospastic heart fail-
re. We recommend performing spasm provocation test in
atients with unknown origin of heart failure and no ﬁxed
tenosis. If coronary artery spasm was provoked, we should
dminister calcium channel blockers and nitrate/nicorandil
n these patients with heart failure. Beta-blocker ther-
py is the ﬁrst-line therapy in patients with heart failure
n the worldwide. However, in patients with heart failure
nd positive spasm, we should administer calcium chan-
el blockers before the administration of beta-blockers to
mprove ischemic ﬁndings due to coronary artery spasm. The
dministration of beta-blockers without calcium channel
lockers/nitrates may lead to the aggravation of coronary
rtery spasm in these patients.
ecessity of spasm provocation test
n this study, rest angina was observed before admission in
nly two patients (17%) in the positive spasm group. More-
ver, typical coronary spastic angina was diagnosed before
dmission in only one patient. Sakata et al. [5] and Nishi et
l. [6] also reported that only spasm provocation test, such
s ACh or ER, can identify these patients with and with-
ut coronary spasm. We could not classify these patients
nto two groups according to their chest symptoms before
dmission. In our study, we could not classify these patients
nto two groups without performing spasm provocation tests.
n patients with left ventricular dysfunction, spasm provo-
ation test has a potential to cause severe complications
nd we should perform spasm provocation tests with careful
ttention [12,13].
ecessity of calcium channel blockers in medical
herapy
n patients with heart failure who had provoked spasm,
edical therapy including calcium channel blockers and
itrate/nicorandil improved left ventricular function on
chocardiography in this study. The signiﬁcant decrease in
eft ventricular end-systolic dimension was observed over
year of medical therapy. Left ventricular end-diastolic
nd end-systolic dimension in patients in the positive spasm
roup was signiﬁcantly smaller than that in patients in the
egative spasm group after medical therapy. In patients
ith heart failure and positive spasm, the administration of
alcium channel blockers is necessary to improve left ven-
ricular function irrespective of its negative inotropic effect.linical implications
eta-blocker therapy is established in patients with heart
ailure worldwide [14,15]. Prognosis is improved in patients
ith heart failure after beta-blocker therapy [16,17]. How-S. Sueda et al.
ver, if patients diagnosed with heart failure had coronary
pasm, single beta-blocker therapy without the administra-
ion of calcium antagonists or nitrate/nicorandil may cause
ggravation of chest symptoms and left ventricular dysfunc-
ion. In Japanese patients, coronary artery spasm is three
imes higher than in Caucasian patients [18—21]. In espe-
ially oriental countries, such as Korea, China, Taiwan, and
apan, the investigation of provoked coronary artery spasm
n patients with heart failure is necessary to medicate these
atients with heart failure accurately.
imitations of this study
his study had several limitations. One is that it was a single
enter retrospective study, not a multi-center prospective
tudy. Second is that we could not perform spasm provo-
ation tests in all patients with heart failure and we could
erform spasm provocation tests in only 18% of patients with
eart failure before discharge and the sample size is small.
hird is that we employed ACh or ER as a spasm provocation
est. Coronary pharmacological response was not the same
etween the two agents, as we already reported [22]. Fourth
s that follow up duration was short, less than 2 years. Fifth is
hat left ventricular diastolic dysfunction was not analyzed
n detail in this study. Further examinations including much
onger follow up periods would be necessary to investigate
eft ventricular function and prognosis in Japanese patients
ith heart failure and coronary artery spasm.
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